ESLC:F:F-ESSILORLUXOTTICA 1/2/O.N. (EUR)

COMMON STOCK | Medical Instruments & Supplies |

Last Closing

USD 121

Change

0.00 (0.00)%

Market Cap

USD 112.84B

Volume

15.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

EssilorLuxottica Société anonyme designs, manufactures, and distributes ophthalmic lenses, frames, and sunglasses in North America, the Middle East, Africa, Europe, Latin America, and the Asia-Pacific. It offers lens, eyewear, contact lenses, reading glasses under the Essilor, Varilux, Crizal, Eyezen, Stellest, Xperio, Transitions, Ray-Ban, Oakley, Barberini, KODAK Lens, Nikon, Shamir, eyexpert, iWear, Humanware, Optifog, Persol, Oliver Peoples, Vogue Eyewear, Arnette, Alain Mikli, Costa, Bliz, Native Eyewear and Bolon, and Foster Grant brands. The company also provides vision assessment, eye pathology diagnosis and treatment, finishing equipment, fitting parameter measurement, small tools, and consumables. In addition, it offers SPECTRALIS, a multimodal imaging platform for the diagnosis and treatment; ANTERION, a multi-disciplinary all-in-one anterior segment imaging solution for measurements; HEYEX 2, an image management and device integration platform; HEYEX EMR, an electronic medical record platform; digital surgical visualization platform; and high-tech equipment for optical surfacing, polishing, measuring, coating, and finishing, as well as consumables, tools, and services under the Satisloh brand. Further, the company designs, develops, markets, and maintains lens edging and mounting instruments for opticians and prescription laboratories; and optometry instruments for eyecare professionals, schools, occupational medicine centers, military, and other institutions. It sells its products to independent opticians, distributors, third-party e-commerce platforms, and large retail chains in the eyecare and eyewear industry; and consumers through the network of brick and mortar retail network and its online channels. The company was formerly known as Essilor International Société Anonyme and changed its name to EssilorLuxottica Société anonyme in October 2018. EssilorLuxottica Société anonyme was founded in 1849 and is headquartered in Paris, France.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-06-05 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
IUI1:F Intuitive Surgical Inc

+0.65 (+0.13%)

USD 180.46B
ESL:F EssilorLuxottica Société ano..

+2.00 (+0.82%)

USD 118.76B
BOX:F Becton Dickinson and Company

+0.15 (+0.10%)

USD 43.29B
HYB0:F HOYA CORP. ADR/ 1 O.N.

-0.50 (-0.50%)

USD 37.66B
HYB:F HOYA Corporation

-1.25 (-1.22%)

USD 37.63B
RME:F ResMed Inc

+1.50 (+0.69%)

USD 32.97B
RMEA:F Resmed Inc DRC

+0.20 (+0.93%)

USD 31.15B
56S0:F RENAU.UNSP.ARD 1/5 EO-20

+0.30 (+1.62%)

USD 20.06B
56S1:F Sartorius Stedim Biotech SA

+0.30 (+0.16%)

USD 19.82B
CBH:F COLOPLAST SP.ADR 1/10 DK1

+0.05 (+0.62%)

USD 19.20B

ETFs Containing ESLC:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.31% 75% C 63% D
Dividend Return 1.74% 83% B 48% F
Total Return 6.05% 75% C 64% D
Trailing 12 Months  
Capital Gain 17.48% 78% C+ 74% C
Dividend Return 1.96% 50% F 23% F
Total Return 19.44% 72% C 68% D+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 13.73% 84% B 74% C
Dividend Return 14.58% 76% C+ 67% D+
Total Return 0.85% 43% F 25% F
Risk Return Profile  
Volatility (Standard Deviation) 15.13% 80% B- 80% B-
Risk Adjusted Return 96.37% 98% N/A 92% A
Market Capitalization 112.84B 98% N/A 98% N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.